Bioxel Pharma Completes cGMP Quality Audit for Paclitaxel Used in Medical Device.SAINTE-FOY, Quebec -- Bioxel Pharma Inc. (TSX TSX Toronto Stock Exchange (TSE before April, 2002) TSX Transfer from Stack Pointer to Index TSX True Space Extension VENTURE:BIP BIP - An incorrect singular of BIPS. One billion instructions per second is 1 BIPS, not 1 BIP. ), a leading manufacturer and supplier of taxane APIs and developer of targeted oncology drugs, today announced that it has completed a vendor qualification audit for paclitaxel paclitaxel /pac·li·tax·el/ (pak?li-tak´sel) an antineoplastic that promotes and stabilizes polymerization of microtubules, isolated from the Pacific yew tree (Taxus brevifolia); carried out by a US-based medical device manufacturer. Bioxel has also won an order for paclitaxel to be used by the customer to complete clinical development of its medical device. The companies are in discussions to enter into a long-term paclitaxel supply relationship. "As with our oncology pharma customers, qualification to supply paclitaxel for medical device comes after a thorough due diligence Research; analysis; your homework. This term has caught on in all industries, because it sounds so "wired." Who would want to do analysis or research when they can do due diligence. See wired. of Bioxel's supply chain," said Pascal Delmas, President and CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. of Bioxel. "Product quality, timely deliveries and competitive pricing are among the key criteria allowing Bioxel to differentiate itself from competition and continue to win paclitaxel business". Bioxel manufactures and sells cGMP paclitaxel to medical device, specialty pharmaceutical and generic companies. The Corporation's dedicated cGMP paclitaxel facility has a 120 kilogram annual capacity and is located at an FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. inspected pharmaceutical manufacturing site in California.The paclitaxel product is registered with US, EU and Canadian regulatory authorities, allowing sales into approved formulated products worldwide. ABOUT BIOXEL PHARMA Bioxel Pharma Inc. is an emerging leader in biopharmaceuticals, focused on developing, manufacturing and marketing taxane pharmaceutical ingredients. Taxanes are used in drug products for the treatment of cancer and other diseases, including psoriasis, rheumatoid arthritis rheumatoid arthritis Chronic, progressive autoimmune disease causing connective-tissue inflammation, mostly in synovial joints. It can occur at any age, is more common in women, and has an unpredictable course. , Alzheimer's disease and cardiovascular disease. The Corporation sells cGMP paclitaxel and develops a portfolio of other generic taxane APIs and taxane-based proprietary products for improved cancer therapy. This announcement includes forward-looking statements that involve a number of risks and uncertainties, the outcome of which could materially and/or adversely affect future results. These include risks and uncertainties that could affect Bioxel's products under development such as regulatory factors, technological developments and competitive factors. Achievement of the objectives set forth in this release is subject to these risks and uncertainties. The Corporation's results, or the measures it adopts, could differ materially from those indicated or underlying these statements, or could have an impact on the realization of financial projections. The TSX Venture Exchange TSX Venture Exchange Originally called the Canadian Venture Exchange (CDNX), this was a result of the merger of the Vancouver and Alberta stock exchanges. The goal of TSX Venture Exchange is to provide venture companies with effective access to capital while protecting investors. has not reviewed the contents of this pre ss release and accepts no responsibility for the adequacy or the accur acy thereof. Bioxel Pharma Inc. (TSX VENTURE:BIP) |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion